Proteome Sciences PLC AGM Statement (2148R)

TIDMPRM

RNS Number : 2148R

Proteome Sciences PLC

26 June 2020

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Annual General Meeting (AGM) Statement

At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:

"Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT(R) and TMTpro(TM) have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these positive trends to continue through the rest of the year".

For further information:

 
 Proteome Sciences plc 
 Dr Ian Pike, Interim Chief Executive        Tel: +44 (0)20 7043 2116 
  Officer & Chief Scientific Officer 
 
  Richard Dennis, Chief Commercial Officer 
 
   Allenby Capital Limited (AIM Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter             Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R) MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGMFFMPTMTJTMJM

(END) Dow Jones Newswires

June 26, 2020 06:00 ET (10:00 GMT)

Proteome Sciences (AQSE:PRM.GB)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025